Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016)

Aytu Biopharma's (AYTU) quarterly Convertible Debt came in at $9797.0 in Q1 2016, down 99.8% quarter-over-quarter from $4.9 million in Q4 2015.

Analysis

Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016) Analysis & Trends

Aytu Biopharma (AYTU) has reported Convertible Debt for 2 consecutive years, with $9797.0 the latest figure, recorded in Q1 2016.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	643.26 Bn	622.50 Bn	17.26 Bn
2	AbbVie	443.31 Bn	436.74 Bn	12.70 Bn
3	Merck	364.74 Bn	357.60 Bn	12.21 Bn
4	Novartis Ag	266.46 Bn	258.77 Bn	11.24 Bn
5	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn
6	Sanofi	52.33 Bn	44.95 Bn	10.79 Bn
7	Revolution Medicines	43.79 Bn	43.79 Bn	-
8	Incyte	25.23 Bn	20.69 Bn	1.57 Bn
9	United Therapeutics	21.67 Bn	19.01 Bn	683.80 Mn
10	Aytu Biopharma	22.49 Mn	-4.22 Mn	7.60 Mn

Historic Data

Download Data